Animal Study Links Inactivation of the Autophagy Gene ATG7 to the Onset of ALS, FTD
Inactivation of ATG7, one of the genes that controls autophagy — a process in which cells degrade or recycle…
Articles by Joana Carvalho, PhD
FDA Names APB-102, Potential Gene Therapy for Familial ALS, an Orphan Drug
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Apic Bio‘s APB-102,…
Fungus Used in Chinese Medicine Reduces Motor Neuron Loss and Prolongs Life in Mouse Model of ALS, Study Shows
The Chinese caterpillar fungus (Hirsutella sinensis), used in traditional Chinese medicine, minimized motor neuron loss and extended the lifespan in…
Structure of Cdc48 May Provide Clues for Designing New ALS Therapies, Study Shows
Scientists who dissected the structure, and mechanism of action, of the protein Cdc48 — dubbed the “Swiss Army knife…
ALS Posture Impairments May Be Marker for Disease Severity, Study Suggests
Posture impairments in amyotrophic lateral sclerosis (ALS) are linked to deficits in trunk control and in the mechanisms that…
ACT Support Program Empowers Caregivers to Cope With Distress, Study Says
Caregivers of people with amyotrophic lateral sclerosis (ALS) and progressive muscular atrophy (PMA) say a Dutch support program…
Histamine-Related Genes May Become Biomarkers and Therapeutic Targets for ALS, Mouse Study Suggests
Histamine-related genes are promising disease biomarkers and therapeutic targets to slow amyotrophic lateral sclerosis (ALS) progression, a mouse study…
Oxford BioDynamics to Use New Technology as Partner in REFINE-ALS Biomarker Study
Oxford BioDynamics has joined the REFINE-ALS study, a project designed to detect and measure the levels of specific biomarkers…
Investigational ALS Treatment NPT520-34 Begins Phase 1 Trial in Healthy Volunteers
NPT520-34, an investigational small molecule for the treatment of Parkinson’s disease and amyotrophic lateral sclerosis (ALS), is being tested…
#AANAM – Reldesemtiv Reduces Lung Function Decline and ALS Progression, Phase 2 Trial Shows
Reldesemtiv (formerly known as CK-2127107) reduces lung function decline and overall disease progression, without significant adverse…